MX2012002761A - Bipiridinas utiles para el tratamiento de enfermedades proliferativas. - Google Patents

Bipiridinas utiles para el tratamiento de enfermedades proliferativas.

Info

Publication number
MX2012002761A
MX2012002761A MX2012002761A MX2012002761A MX2012002761A MX 2012002761 A MX2012002761 A MX 2012002761A MX 2012002761 A MX2012002761 A MX 2012002761A MX 2012002761 A MX2012002761 A MX 2012002761A MX 2012002761 A MX2012002761 A MX 2012002761A
Authority
MX
Mexico
Prior art keywords
bipyridines
useful
treatment
proliferative diseases
formula
Prior art date
Application number
MX2012002761A
Other languages
English (en)
Inventor
Simon C Ng
Martin Sendzik
Paul A Barsanti
Keith B Pfister
James Sutton
Cheng Hu
Xianming Jin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012002761A publication Critical patent/MX2012002761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención proporciona los compuestos de la fórmula (I): (ver fórmula (I)) y las sales farmacéuticamente aceptables de los mismos. También se proporciona un método para utilizar un compuesto de la fórmula I para el tratamiento de una enfermedad o condición mediada por un inhibidor de la cinasa dependiente de ciclina (CDK).
MX2012002761A 2009-09-04 2010-09-02 Bipiridinas utiles para el tratamiento de enfermedades proliferativas. MX2012002761A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27593809P 2009-09-04 2009-09-04
US28496109P 2009-12-28 2009-12-28
PCT/EP2010/062893 WO2011026911A1 (en) 2009-09-04 2010-09-02 Bipyridines useful for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
MX2012002761A true MX2012002761A (es) 2012-04-19

Family

ID=43478200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002761A MX2012002761A (es) 2009-09-04 2010-09-02 Bipiridinas utiles para el tratamiento de enfermedades proliferativas.

Country Status (11)

Country Link
US (1) US20110130380A1 (es)
EP (1) EP2473499A1 (es)
KR (1) KR20120092586A (es)
CN (1) CN102471310A (es)
AR (1) AR078321A1 (es)
AU (1) AU2010291206A1 (es)
CA (1) CA2771563A1 (es)
MX (1) MX2012002761A (es)
TW (1) TW201113273A (es)
UY (1) UY32877A (es)
WO (1) WO2011026911A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US20130303507A1 (en) * 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
GEP20196983B (en) * 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017345367A1 (en) 2016-10-20 2019-04-04 Pfizer Inc. Anti-proliferative agents for treating PAH
CA3161351A1 (en) * 2019-12-09 2021-06-17 Zhenyu Wang Compound as cyclin-dependent kinase 9 inhibitor and use thereof
CN115381824A (zh) * 2021-05-24 2022-11-25 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN115448874A (zh) * 2021-06-09 2022-12-09 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
EA200900799A1 (ru) * 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями

Also Published As

Publication number Publication date
TW201113273A (en) 2011-04-16
AU2010291206A1 (en) 2012-02-23
EP2473499A1 (en) 2012-07-11
CA2771563A1 (en) 2011-03-10
KR20120092586A (ko) 2012-08-21
AR078321A1 (es) 2011-11-02
UY32877A (es) 2011-04-29
WO2011026911A1 (en) 2011-03-10
US20110130380A1 (en) 2011-06-02
CN102471310A (zh) 2012-05-23
WO2011026911A8 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
JO2885B1 (en) Protein kinase inhibitors
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
EA201391319A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
JO2848B1 (en) Organic compounds
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
AU2012214029A8 (en) Rorgammat inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX346186B (es) Inhibidores de proteina cinasas.
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MY185103A (en) Bezylamine derivatives as inhibitors of plasma kallikrein
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
IN2012DN02502A (es)
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal